Assessing Patient-Reported Financial Hardship in Patients With Cancer in Routine Clinical Care. Issue 11 (27th November 2022)

• Record Type: Journal Article
• Authors: Voleti, Sandeep S.; Warsame, Rahma; Mead-Harvey, Carolyn; Ailawadhi, Sikander; Jain, Atul; Fonseca, Rafael; Griffin, Joan M.; Khera, Nandita
• Is Part Of: JCO oncology practice. Volume 18:Issue 11(2022)
• Page Start: e1839
• Page End: e1853
• Publication Date: 2022-11-27
• Subjects: Oncology -- Periodicals; Medical Oncology; Neoplasms; Oncology; Periodicals; 616.994
• DOI: 10.1200/OP.22.00276
• Languages: English
• ISSNs: 2688-1527

Abstract

Abstract : PURPOSE: Financial hardship (FH) in cancer care is a growing challenge for patients, their caregivers, and health care providers with impact on morbidity and mortality. In this study, we report on a standardized approach to describe the prevalence and predictors for FH as part of routine clinical workflow. We also report on the association of FH with survival in our cancer patient population. METHODS: This study includes patients who completed a FH screen at least once between 2018 and 2020. Demographics, disease state, and mortality data were extracted from the medical records. Multivariable logistic regression models were used to examine association of sociodemographic and disease variables with FH. By using propensity score weighting to account for differences in demographic and clinical factors between patients with and without FH, we then fit Cox proportional hazards models to examine the relationship between FH and survival. RESULTS: The study cohort included 31, 154 patients. FH was reported by 14% (n = 4, 250) of the patients. A significantly higher likelihood of having FH ( P < .001 for all) was reported by racial/ethnic minority patients; those who were unemployed/disabled, single, or divorced; patients from disadvantaged neighborhoods; and those who were self-pay or had government insurance. Older age, being retired, and living farther from the cancer center were associated with significantly less likelihood of endorsing FH. Patients who endorsed FH had a lower survival (hazard ratio for mortality 1.46). CONCLUSION: Our study identified key groups more likely to report FH in a relatively affluent population at a large cancer center and showed an adverse association between FH and survival. Further research is needed to develop clinical care pathways for patients at high risk for worse financial and clinical outcomes.